Robert Potashnick was named Chief Accounting Officer of Envoy Medical, Inc. As of November 6, 2026, Envoy Medical, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 21, 2026 to August 27, 2026, naming 2 appointments (Form 8-K, August 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Envoy Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Envoy Medical, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-21 to 2026-08-27. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Envoy Medical, Inc. files it.
Also on the record for Envoy Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 14, 2026 | Stake report, Schedule 13G/A, by Alta Partners LLC | 2.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G, by Bleichroeder LP | 9.99% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | 3.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13D/A, by Glen A. Taylor | 84.8% of the class | 5%+ stakes | Source |
| February 12, 2026 | IPO filing, Form 424B4 | $0.4 a share | IPO filings | Source |
| February 12, 2026 | IPO filing, Form 424B4 | $0.4 a share | IPO filings | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Ayrton Capital LLC | 7.87% of the class | 5%+ stakes | Source |
| February 10, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 6, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 18, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| December 8, 2025 | Stake report, Schedule 13D, by Glen A. Taylor | 44.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Envoy Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Envoy Medical, Inc. and the records around it.
Envoy Medical, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- IPO filing Feb 2026
- Who owns it
Companies that share a holder
- Bleichroeder LP also filed stake reports on 16 other companies: MDxHealth SA (Oct 2026), Identiv, Inc. (INVE) (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Watch Envoy Medical, Inc.
Get an email when Envoy Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Envoy Medical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Envoy Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Envoy Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-27 | In | Chief Accounting Officer | 8-K, 2026-08-27 | ||
| 2026-04-21 | In | Director | 8-K, 2026-04-21 |
Who leads Envoy Medical, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Robert Potashnick, appointed (filed 2026-08-27).
- Director: Charles S. McKhann, appointed (filed 2026-04-21).
New leaders reset buying decisions — get the Full Report on Envoy Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Envoy Medical, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Envoy Medical, Inc.Every change, in the filing's words
Appointed: Robert Potashnick, Chief Accounting Officer
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On August 24, 2026, Envoy Medical, Inc. (the "Company") appointed Robert Potashnick to serve as the Company's Chief Accounting Officer and Vice President of Finance.
- Mr. Potashnick had previously served as Interim-Chief Financial Officer of the Company on a contractor basis.
- Mr. Potashnick will continue the duties as the Company's principal financial officer and principal accounting officer.
- Mr. Potashnick was hired to serve as Chief Accounting Officer and Vice President of Finance pursuant to the terms of an Employment Agreement dated August 24, 2026 (the "Employment Agreement").
- Pursuant to the terms of the Employment Agreement, Mr. Potashnick is entitled to a base salary of $315,000 per year, an initial target bonus equal to 15% of his base salary payable upon the Company's achievement of certain performance goals, and an initial equity award of 250,000 stock options at an exercise price of $0.746 per share, the closing price of the Company's Class A Common Stock on the hire date.
- The Employment Agreement also provides for six months of severance compensation in connection with certain terminations of Mr. Potashnick's employment.
- Mr. Potashnick, 46, has provided consulting services through Oasis Business Consulting, LLC since October 2024, including to the Company beginning in June 2025.
- Previously, Mr. Potashnick served as the Chief Financial Officer of Flutterbee Education Group from January 2024 to October 2024 and FOXO Technologies, Inc. (NYSE American: FOXO) from January 2021 to September 2023.
Appointed: Charles S. McKhann, Director
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the " Board ") of Envoy Medical, Inc. (the " Company "), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company's 2027 annual meeting of stockholders.
- In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Board's Compensation Committee (the "Compensation Committee").
- Also in connection with his appointment, the size of the Board was increased from six members to seven members.
- Mr. McKhann currently serves as a director of Exagen, Inc., a publicly traded diagnostics company, and as Executive Chairman at Distalmotion SA, a privately held surgical robotics company.
- Previously, Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical, Inc. ("Silk Road"), a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery, Inc. ("Apollo"), a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific Corporation.
- From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical, Inc., a medical device company.
- From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical, Inc., a medical device company acquired by Johnson & Johnson in April 2017.
Tools for this story
Each opens in a new tab, filled in for Envoy Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.